Caplin Point gets Colombia nod for Softgel Capsules division

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-05-06 08:00 GMT   |   Update On 2024-05-06 08:00 GMT
Advertisement

Chennai: Caplin Point Laboratories Limited has received Colombia's INVIMA approval for its Softgel Capsules division at Puducherry.

The site inspection of Unit-1 was completed on May 3rd and found compliant as per INVlMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).

Commenting on the approval, Mr.C.C.Paarthipan, Chairman, Caplin Point Laboratories Limited said “Expansion into larger markets of Latin America such as Colombia, is an important aspect of our future growth, and this approval, especially in the niche Softgel Capsules range will contribute well to the same.”

The Unit currently caters to Emerging Markets of Latin America and Africa with a variety of dosage forms such as Tablets, Capsules, Softgel Capsules, Suppositories, Liquid Orals, Topicals and Injectables.

Read also: Caplin Steriles gets USFDA nod for Ofloxacin Otic Solution

Caplin Point Laboratories Limited is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. 

Read also: USFDA grants nod for Caplin Steriles Ofloxacin Ophthalmic Solution




Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News